225 results on '"Agulnik J"'
Search Results
2. MA10.06 CARMA-BROS: CAncers with Rare Molecular Alterations - Basket-umbrella Real-world Observational Study
3. EP12.03-02 Previously Treated Advanced-Disease NSCLC KRAS G12C From a Canadian Multi-Institutional Real-World Evidence Database (CARMA)
4. 91P Treatment (tx) patterns and outcomes in resectable early-stage non-small cell lung cancer (NSCLC): A global real-world (rw) study
5. 147TiP Exactis-01 - Clinical utility of returning liquid biopsy NGS results in NSCL cancer patients: A Canadian trial through the Exactis Network
6. EP06.01-001 The Longitudinal Impact of COVID-19 on the Diagnosis and Treatment of Lung Cancer at a Canadian Academic Centre: A Retrospective Chart Review
7. EP04.02-004 The Patient Impact of Liquid Biopsy - Health-Related Quality of Life in Patients Undergoing Liquid Biopsy for Advanced Non-Small Cell Lung Cancer
8. EP03.01-016 The Canadian Small Cell Lung Cancer Database (CASCADE): Results from a Multi-Institutional Real-World Evidence Collaboration
9. EP11.03-001 Loss of SUSD2 Expression in Lung Adenocarcinoma Correlates with Solid Pattern, Higher Histological Grading and Higher Ki-67 Cycling Index
10. EP14.04-001 Treatment and Outcomes of Patients with Limited-Stage Small-cell Lung Cancer in the Canadian SCLC Database (CASCADE)
11. EP14.05-020 Population-based Outcomes for Patients with Extensive-Stage Small-cell Lung Cancer from the Canadian SCLC Database (CASCADE)
12. EP05.02-019 Transitioning to Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: Surgical Outcomes in a Regionalized Pulmonary Oncology Network
13. What constitutes best supportive care in the treatment of advanced non-small cell lung cancer patients?—Results from the lung cancer economics and outcomes research (LUCEOR) study
14. P3.06D.08 ctDNA-NGS Assay (Liquid Biopsy) for Non-Small Cell Lung Cancer: Utility of Plasma Cell-Free DNA and Tissue NGS in Detecting Genetic Mutations
15. 1798P Relapsed and refractory systemic therapy real-world outcomes in the Canadian small cell lung cancer database (CASCADE)
16. 1793P Treatment and outcomes of limited disease small cell lung cancer (LD-SCLC) in the Canadian small cell lung cancer database (CASCADE)
17. OA16.02 The Economic Value of Liquid Biopsy for Genomic Profiling in Advanced Non-Small Cell Lung Cancer
18. P64.01 The Canadian Small Cell Lung Cancer Database (CASCaDe): A Multi-Institutional Real-World Evidence Collaboration
19. P31.01 Impact of COVID-19 on Lung Cancer Diagnosis and Treatment: A Retrospective Chart Review
20. P24.11 Cell-Free Tumor DNA (ctDNA) Utility in Detection and Monitoring EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC)
21. 1425P Clinical utility of liquid biopsy for the early diagnosis of EGFR mutant advanced lung cancer in real-life setting (CLEAR)
22. P89.03 Demonstrating VALUE of Liquid Biopsy for Lung Cancer in a Public Healthcare System
23. The metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma
24. Understanding Clinical Practice and Survival Outcomes in Patients with Unresectable Stage III Non-Small-Cell Lung Cancer in a Single Centre in Quebec
25. 1195P The value of detecting resistance through liquid biopsy
26. P1.01-99 EGFR-Wild Type Patients Responding to TKI: Revisiting Pathology with Newer Technology
27. Erratum to “The metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma” [Lung Cancer 132 (June) (2019) 36–38]
28. P1.01-52 Cell-Free Tumor DNA (ctDNA) Utility in Detection of Original Sensitizing and Resistant EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC)
29. MA16.09 Clinical Practice and Outcomes in Patients with Stage III Unresectable Non-Small-Cell Lung Canceran Academic Centre, Canada
30. Crizotinib Inhibition of ROS1-Positive Tumours in Advanced Non-Small-Cell Lung Cancer: A Canadian Perspective
31. Detection of T790M Mutation in Blood Versus Tumor Tissue Biopsy
32. Does the Presence of Emphysema Increase the Risk of Radiation Pneumonitis in Lung Cancer Patients?
33. P1.04-16 Comparison of Clinical Response to Checkpoint Inhibitors in Advanced NSCLC with High PD-L1 Expression Tested on Cytology Versus Biopsy Samples
34. P2.09-07 Does Metastatic Site Matter for PD-L1 Testing in Stage IV NSCLC?
35. MA09.09 EBUS-TBNA in Assessing PD-L1 Expression in NSCLC
36. P2.01-23 Baseline Plasma Biomarkers Predict Long-Term Responses to ALK-TKIs in ALK+ Advanced Non-Small Cell Lung Cancer (NSCLC)
37. P2.01-04 Reducing Time to Molecular Diagnosis for Advanced NSCLC in the Context of a Reference Testing Center
38. MA02.11 Achieving Value in Cancer Diagnostics: Blood Versus Tissue Molecular Profiling - A Prospective Canadian Study (VALUE)
39. MA21.09 Differential Gene Expression in Tumor and Normal Tissue Reveals New Insights in the Biology of Non-Small Cell Lung Carcinoma.
40. Canadian Perspectives: Update on Inhibition of ALK-Positive Tumours in Advanced Non-Small-Cell Lung Cancer
41. A012 – CURRENT UTILIZATION OF AEROBIC EXERCISE IN ADULT NEUROLOGICAL REHABILITATION BY CANADIAN PHYSIOTHERAPISTS
42. PUB079 Detection of the EGFR P.(T790M) Mutation by Different Methods: A Small Comparison Case Study
43. P2.02-040 Cytology Cell Block Is Suitable for Immunohistochemical Testing for PD-L1 in Lung Cancer
44. P3.02-055 Detecting ALK, ROS1 and RET Gene Translocations in Non-Small Cell Lung Cancer (NSCLC) with the NanoString Platform
45. Lung Cancer Care Trajectory at a Canadian Centre: An Evaluation of How Wait Times Affect Clinical Outcomes
46. An exploratory comparative analysis of tyrosine kinase inhibitors or docetaxel in second-line treatment of EGFR wild-type non-small-cell lung cancer: a retrospective real-world practice review at a single tertiary care centre
47. Canadian Consensus: Inhibition of Alk-Positive Tumours in Advanced Non-Small-Cell Lung Cancer
48. Kinase Inhibitors or Docetaxel in Second-Line Treatment of EGFR Wild-Type Non-small-Cell Lung Cancer: A Retrospective Real-World Practice Review at a Single Tertiary Care Centre
49. Montreal prognostic score: estimating survival of patients with non-small cell lung cancer using clinical biomarkers
50. The Potential Role for Acupuncture in Treating Symptoms in Patients with Lung Cancer: An Observational Longitudinal Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.